Cardiovascular and metabolic effects of adenosine A1-receptor agonists in streptozotocin-treated rats

Journal of Cardiovascular Pharmacology

Volumn 29, Issue 3, 1997, Pages 417-426

  Cox, Bryan F ^a,b   Clark, Kenneth L ^a   Perrone, Mark H ^a   Welzel, Gustav E ^a   Greenland, Brett D ^a   Colussi, Dennis J ^a   Merkel, Linda A ^a  

^a Rhône Poulenc Rorer ^*  (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Adipocytes; Arterial pressure; Free fatty acids; Glucose; Heart rate; Non insulin dependent diabetes mellitus; Triglycerides

Indexed keywords

6 N CYCLOHEXYL 2' O METHYLADENOSINE; 6 N CYCLOPENTYLADENOSINE; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE DEAMINASE; BRAIN RECEPTOR; DRUG VEHICLE; FATTY ACID; GLUCOSE; GLYCEROL; METHYLCELLULOSE; NORADRENALIN; RG 14202; STREPTOZOCIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; HEART RATE; HEMODYNAMICS; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIPOLYSIS; MALE; MEAN ARTERIAL PRESSURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; STREPTOZOCIN DIABETES;

ADENOSINE; ADENOSINE DEAMINASE; ADIPOCYTES; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; CYCLOPENTANES; DIABETES MELLITUS, EXPERIMENTAL; FATTY ACIDS, NONESTERIFIED; GLYCEROL; HEART RATE; LIPOLYSIS; MALE; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PURINERGIC P1; TRIGLYCERIDES;

EID: 0031002118     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199703000-00017     Document Type: Article

References (26)

1. Leung E, Johnson CI, Woodcock EA. A comparison between the adenosine receptors mediating adenylate cyclase inhibition and cardiac depression in the guinea pig heart. J Cardiovasc Pharmacol 1986;8:1003-8.
2. 1 receptors. J Pharmacol Exp Ther 1987;244:478-84.
3. Webb RL, McNeil RB, Barclay BW, Yasay G. Hemodynamic effects of adenosine agonists in the conscious spontaneously hypertensive rat. J Pharmacol Exp Ther 1990;254:1090-9.
4. Mustafa JS, Askar AO. Evidence suggesting an Ra type adenosine receptor in bovine coronary arteries. J Pharmacol Exp Ther 1985; 232:49-56.
5. Coffin VL, Spealman RD. Behavioral and cardiovascular effects of analogs of adenosine in cynomolgus monkeys. J Pharmacol Exp Ther 1987;241:76-83.
6. Smits GJ, Kitzen JM, Perrone MH, Cox BF. Angiotensin subtype 1 blockade selectively potentiates adenosine subtype 2-mediated vasodilation. Hypertension 1993;22:221-30.
7. 1-selective adenosine agonist, RG14202. J Pharmacol Exp Ther 1993;265:699-706.
8. Londos C, Cooper DMF, Wolff J. Subclasses of external adenosine receptors. Proc Natl Acad Sci U S A 1980;77:2552-4.
9. Foley JE. Rationale and application of fatty acid oxidation inhibitors in the treatment of diabetes mellitus. Diabetes Care 1992;15:773-84.
10. Reaven G. Role of insulin resistance in human disease. Diabetes 1988;37:11595-607.
11. Reaven G, Chang H, Ho H, Jeng C-Y, Hoffman B. Lowering of plasma glucose in diabetic rats by antilipolytic agents. Am J Physiol 1988;254:E23-30.
12. Dulbecco A, Albenga C, Borretta G, Vacca G, Milanesi G, Lavezzori M. Effect of acipimox on plasma glucose levels in patients with non-insulin dependent diabetes mellitus. Curr Ther Res Clin Exp 1989;46:478-83.
13. Saloranta C, Franssila-Kallunki A, Ekstrand A, Taskinen M, Groop L. Modulation of hepatic glucose production by non-esterified fatty acids in type II (non-insulin dependent) diabetes mellitus. Diabetologia 1991;34:409-15.
14. Hoffman B, Dall'aglio E, Hollenbeck C, Chang H, Reaven G. Suppression of free fatty acids and triglycerides in normal and hypertriglyceridemic rats by the adenosine receptor agonist phenylisopropyladenosine. J Pharmacol Exp Ther 1986;239:715-8.
15. Strong P, Anderson R, Coates J, et al. Suppression of non-esterified free fatty acids and triacylglycerol in experimental animals by the adenosine analog GR79236. Clin Sci 1993;84:663-9.
16. 6(carboxamido-3-propylamino)-6-(triproprionyl) 2′3′5′b(d-ribosyl)-9-purine. Res Comm Chem Pathol Pharmacol 1992;75:291-307.
17. 6-sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective adenosine agonists. J Med Chem 1992;35:4143-9.
18. Schaumann E, Kutscha W. Klinisch-pharmakologische Untersuchungen mit einem neuen peroral wirksamen Adenosinderivat. Arzneimittelforschung 1972;22:783-90.
19. Quabbe H-J, Luyckx AS, L'Age M, Schwarz C. Growth hormone, cortisol and glucagon concentrations during plasma free fatty acid depression: different effects of nicotinic acid and an adenosine derivate (B.M.11,189). J Clin Endocrinol Metab 1983;57: 410-4.
20. Merkel LA, Hawkins ED, Colussi DJ, et al. Cardiovascular and antilipolytic effects of the adenosine agonist GR79236. Pharmacology 1995;51:224-36.
21. Noma A, Okabe H, Kita M. A new colorimetric microdetermination of free fatty acids in serum. Clin Chim Acta 1973;43:317-20.
22. 1 receptor agonist. Drug Devel Res 1995;34:276-88.
23. Zapf J, Feuerlein D, Waldvogel M, Froesch ER. Increased sensitivity of diabetic rat adipose tissue towards the lipolytic action of epinephrine. Diabetologia 1975;11:509-16.
24. Solomon SS, Schwartz Y, Rawlinson T. Lipolysis in diabetic adipocytes: differences in response to growth hormone and adenosine. Endocrinology 1987;121:1056-60.
25. 2 receptors of adenosine agonists and antagonists and their effects on heart rate and coronary vascular tone. J Pharmacol Exp Ther 1988;247:882-8.
26. Casati C, Monopoli A, Forlani A, Bonizzoni E, Ongini E. Telemetry monitoring of hemodynamic effects induced over time by adenosine agonists in spontaneously hypertensive rats. J Pharmacol Exp Ther 1995;275:914-9.